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DOI 10.1186/s12992-017-0280-2RESEARCH Open AccessMethods for medical device and
equipment procurement and prioritization
within low- and middle-income countries:
findings of a systematic literature review
Karin Diaconu1,3*, Yen-Fu Chen2, Carole Cummins1*, Gabriela Jimenez Moyao4, Semira Manaseki-Holland1
and Richard Lilford2Abstract
Background: Forty to 70 % of medical devices and equipment in low- and middle-income countries are broken,
unused or unfit for purpose; this impairs service delivery to patients and results in lost resources. Undiscerning
procurement processes are at the heart of this issue.
We conducted a systematic review of the literature to August 2013 with no time or language restrictions to identify
what product selection or prioritization methods are recommended or used for medical device and equipment
procurement planning within low- and middle-income countries. We explore the factors/evidence-base proposed
for consideration within such methods and identify prioritization criteria.
Results: We included 217 documents (corresponding to 250 texts) in the narrative synthesis. Of these 111 featured in
the meta-summary. We identify experience and needs-based methods used to reach procurement decisions. Equipment
costs (including maintenance) and health needs are the dominant issues considered. Extracted data suggest
that procurement officials should prioritize devices with low- and middle-income country appropriate
technical specifications – i.e. devices and equipment that can be used given available human resources,
infrastructure and maintenance capacity.
Conclusion: Suboptimal device use is directly linked to incomplete costing and inadequate consideration of
maintenance services and user training during procurement planning. Accurate estimation of life-cycle costing and careful
consideration of device servicing are of crucial importance.
Keywords: Medical devices, Prioritization, Resource allocation, Equipment, Health technology assessmentBackground
The absence of safe, effective and well-functioning med-
ical devices and equipment (MDEs) impairs health service
provision, leads to poor patient outcomes and poses sub-
stantial health system and national security risks [1–3].
Nowhere has this been more evident than the recent
Ebola Virus Disease outbreak in West Africa [4–6]. The
absence of laboratory equipment to enable quick and ac-
curate diagnosis, and personal protective equipment to* Correspondence: kdiaconu@qmu.ac.uk; c.l.cummins.20@bham.ac.uk
1Institute for Applied Health Research, University of Birmingham, B15 2TT,
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(http://creativecommons.org/publicdomain/zeensure effective infection prevention and control measures
and health worker safety, directly resulted in delays to
emergency response, difficulties in care delivery and lost
patient and health worker lives [6].
The absence of appropriate technologies impairs more
than emergency care, however: routine services in mater-
nal, child and reproductive care (e.g. immunizations or re-
productive control), interventions for non-communicable
(e.g. diabetes management) and communicable diseases
(e.g. HIV/AIDS diagnosis) all require suitable infrastruc-
ture and functioning technologies. From basic products
such as weighing scales and condoms, to glucometers and
flow-cytometers, health service delivery is predicated uponle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ability of MDEs [1].
Estimates suggest that between 40 and 70% of MDEs
in resource poor settings are broken, unused or unfit for
purpose [7]. Indiscriminate procurement methods, a
mismatch in technology design and demand, high costs
as well as deployment, maintenance and human resource
training challenges all contribute towards this issue [1].
Low- and middle-income countries (LMICs) particularly
lack the regulatory authorities, or biomedical engineer-
ing capacity, to advise on what MDEs are suitable for
use in harsh deployment settings: i.e. facilities with high
temperature, fluctuating electricity or no clean water
supply. The problem is compounded by a mismatch in
MDE supply: manufacturers are located and attuned to
users in lucrative high-income markets [8]. Installation,
preventive and corrective maintenance services and user
training programs are also traditionally absent in LMICs,
leading to unsafe device handling practices with poten-
tially harmful consequences for patients (e.g. in cases of
misdiagnosis due to mis-calibration or infection propa-
gation due to device re-use).
This paper targets one aspect of the above problem:
MDE procurement and resource allocation in LMICs. To
assist decision-makers in conducting informed and
evidence-based product selection decisions, we have
conducted a systematic review of internationally re-
commended methods for procurement planning and
prioritization in settings experiencing severe resource con-
straints, describing the context for these activities and
summarising normative recommendations. Little is known
about how MDE procurement takes place within resource-
constrained settings; the WHO Baseline Surveys on Med-
ical Devices are recent attempts to explore this [9, 10]. The
survey’s findings suggest that LMICs predominantly
conduct procurement at central ministry level within the
public sector [9]; however, the surveys do not provide fur-
ther granular information on how LMIC conduct or plan
MDE procurement. For the purposes of this paper, we
adopt the MDE definition laid out by the Global
Harmonization Task Force and WHO [11, 12].
The identification of best practices and common pit-
falls in MDE procurement may lead to improvements
in MDE management and use. This would not only en-
sure improved use of scarce financial resources, but
also translate to devices being operational and used
competently for improved patient care. The systematic
review is particularly timely given global efforts for
health system strengthening in LMICs: MDEs are rec-
ognized as critical components in ensuring health sys-
tem resilience to shocks and in achieving universal
health coverage. Substantial increases in MDE
utilization have already been noted in middle-income
countries in Europe in line with expanding provision ofhealth care services; similar trends will undoubtedly fol-
low in LMICs globally [13].
We proceed to report the methods and findings of a
systematic literature review of the LMIC relevant MDE
literature aiming to explore the following research
questions:
1. Who are the key stakeholders engaged in
procurement planning and what activities/
interactions do they engage in?
2. What methods inform procurement planning?
3. What factors are considered in procurement
planning?
4. What factors affect successful deployment and use
of MDEs?
5. Where specific prioritisation algorithms exist to
guide procurement, what criteria do said algorithms
use?
6. What are current recommendations for improving
procurement?
Methods
A full account of methods is available in the study
protocol [14].
Searches and study selection
We searched both bibliographic databases and grey lit-
erature up to August 2013 with no language or time re-
strictions imposed and selected documents according to
pre-specified screening and eligibility criteria. Table 1
lists sources searched and Fig. 1 illustrates abstract
selection criteria; Additional files 1 and 2 include details
on the OVID MEDLINE search string and search and
selection algorithm used.
Searches retrieved documents referencing MDEs,
LMICs and procurement. Two independent reviewers
(KD and SB) screened titles for relevance, discarding
documents not referencing MDEs. KD and MB further
screened abstracts according to pre-specified inclusion/
exclusion criteria (Fig. 1). We retained documents with
explicit references to MDE procurement processes or
procedures within LMICs and excluded material focus-
ing on the procurement/evaluation of a single device or
solely on LMIC medical technology regulatory issues.
Disagreements on the inclusion/exclusion of studies in-
volved consultation of a third reviewer (SB) and were
resolved by consensus.
Data collection
One reviewer (KD or MB) extracted data on a pre-
specified list of questions from all included documents.
(See protocol) Questions related to: normative or descrip-
tive accounts of MDE procurement and technology
management processes; the relevance of health technology
Table 1 Sources searched
Search type Search sources
OVID Medline searched as per
search algorithm detailed in
protocol
Bibliographic
databases
OVID Medline, OVID Embase, Cochrane Library, CEA Registry, HMIC, Econlit, VHL
Portal (includes LILACS), African Index Medicus, NHS EED, Web of Science (including CPCI)
Key word searches Website searches TRIP, National Guideline Clearinghouse, Office of health economics International Guideline
Library, CHEPA, CHE York
HTAi, CADTH, INAHTA
Organizational databases
/websites
WHO e-health documentation centre and WHO website, UNICEF, UNAIDS
UNFPA, African development bank, Asian Development Bank, EBRD, World Bank, MSF,
UNDP, UNFPA
National/regional donor
or research agencies
DFID, MSH, AUSAID, GIZ, BMZ, JICA, SWISSAID, CIDA (Canada), DANIDA, AFD, ACORD,
SIDA, IAC
Grey literature ZETOC
a Pascal was mentioned in the protocol but was not accessible; ‘Solutions for public health’, BMJ Clinical Evidence and EBRD were searched but found not relevant
– searches were discontinued
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procurement; the input of health care professionals or
specialist staff (e.g. biomedical engineers, economists)
in procurement decisions; device installation, main-
tenance and decommissioning procedures/recommen-
dations; health service delivery levels and clinical
guideline procurement recommendations; budget im-
pact, technology costs and intended national/regional
coverage levels. We ascertained if documents included
explicit accounts of MDE prioritization processes and
extracted quotations or descriptions of processes for
qualitative analysis.Fig. 1 Abstract selection algorithm and criteria*. * All abstracts were reviewAnalysis
We employed two methods of analysis to summarize
and interpret data extracted. (Additional file 2) Narrative
synthesis was used to offer a summative and descriptive
overview of all included documents for issues relevant to
research questions posed [15]. Qualitative meta-
summary was used to explore MDE prioritization for a
subset of documents outlining explicit prioritization
methods/processes. We iteratively applied descriptive
codes to the extracted data and then grouped similar
codes into categories and themes; effect sizes are calcu-
lated as per Sandelowski et al. and indicate the % ofed in light of the above questions
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gent patterns and relationships between themes to arrive
at summative findings [16].
Reporting
We follow PRISMA reporting guidelines as applicable –
See Additional file 3 for a PRISMA checklist [14, 17].
Role of funding source
The funder of the study had no role in study design, data
collection, analysis and interpretation or writing of the
report. The corresponding authors have full access to all
the data in the study and had final responsibility for the
decision to submit for publication.
Results
Bibliometric analysis
Our search strategy located 11,220 unique documents of
which we selected 217 for inclusion in the systematic re-
view, all published 1984–2013. As several documents re-
trieved were entire books or journal issues where more
than one chapter or article met our inclusion criteria, we
extracted data from 250 individual full-texts. Figure 2
shows a PRISMA flow-chart outlining the study selec-
tion process and Additional file 4 includes a full refer-
ence list of included documents (marked SR# in Tables),
ancillary characteristics and data extracted.
Tables 2 and 3 present characteristics of documents
included. The majority are peer-reviewed journal articles
(n = 125, 50%) and recommendations or guideline docu-
ments. (n = 72, 29%) The WHO and other UN associ-
ated organizations authored 141 (56%) documents. Only
50 (20%) documents refer to specific countries or re-
gions, the remaining documents referencing resource
poor settings or LMICs in general (Table 3).
As procurement methods may differ by technology, we
extracted data on cited health conditions/clinical interven-
tions (Table 4) and MDE descriptions (Additional file 5).
Predominantly, documents reference HIV/AIDS and asso-
ciated comorbidities (n = 29, 12%) and interventions for
reproductive, maternal and child health. (n = 23, 9%)
MDEs cited include laboratory devices (n = 22, 9%),
equipment for surgical care (n = 16, 6%) and reproductive
health (n = 16, 6%). Various classification systems for
equipment or devices were used, including categorization
according to size, cost, clinical area or health service deli-
very level (Additional file 5).
Procurement structures and relevant stakeholders
We distinguish descriptions of MDE procurement struc-
tures – i.e. how stakeholders interact and reach deci-
sions, from procurement methods – i.e. algorithms or
approaches used to determine which technologies to
purchase.Appraised documents identify different stakeholder
groups interacting to reach procurement decisions;
stakeholders range from international donor agencies,
LMIC governments and ministries of health to individ-
ual LMIC health facilities. We classify stakeholders de-
scriptively according to the health system level at which
they operate and provide a summary of their attributed
roles in Fig. 3. We note that procurement activities fre-
quently involve all stakeholder groups outlined; we iden-
tified only one document where donors solely undertook
procurement activities on behalf of LMICs [18].
At macro level, international donor agencies and LMIC
governments engage in procurement partnerships. LMICs
possess the human resource and health system capacity to
support donor campaigns; in turn, donors share financial
and technical resources. For example, Management
Sciences for Health (on behalf of USAID) prompted the
government in Afghanistan to use health economic and
ethical criteria in defining the basic and hospital care
package [19, 20]. Donors (e.g. USAID) and international
agencies (e.g. UNICEF) enjoy a greater share of market
power than LMICs due to their involvement in multi-
country procurement. Donors thus provide an advanta-
geous negotiation position for LMICs, helping secure
flexible payment or bulk-pricing arrangements [21, 22].
Potential disadvantages of donor involvement include
sudden discontinuation of assistance arrangements and
restrictions on financial aid [22]. For example, donors may
restrict financing to countries adhering to strict pro-
curement/tendering regulations; such restrictions may
preclude LMIC governments from strengthening
technology-manufacturing capacity through the award of
national procurement contracts [21]. Similarly, funding
opportunities may be restricted to donor-preferred causes
such as HIV/AIDS diagnosis and treatment, and preclude
investments into incipient health system infrastructures,
including for example sanitary provisions (e.g. water and
sewage), electricity supply and infection prevention and
control protocols [23].
At meso level LMIC governments, their ministries of
health and relevant subunits engage in the minutiae of ac-
quisition planning, tendering and equipment distribution/
oversight activities. Stakeholders set procurement targets -
i.e. project what equipment to procure via the use of experi-
ence or needs based planning methods (see next section) -
and agree national technology distribution plans [1, 24].
Not all medical device procurement decisions are
made at regional, country or supra-national level: indi-
vidual health facilities also engage in direct acquisition
[25, 26]. Authors of reviewed documents caution that
such practices are not consistent across LMICs: hospitals
frequently lack dedicated funding for MDE procurement
and may instead rely on donations, reuse and recycling
practices, to meet technological needs [25, 27, 28].
Fig. 2 PRISMA Flowchart
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cesses, we note the literature is largely unclear on how
stakeholder views are aggregated or divergent opinions
handled - we have identified only three documents in-
cluding descriptions of such accounts. Nobre et al. point
to the usefulness of multi-criteria decision analysis
methods, aimed to aggregate and integrate individual
decision-makers opinions [29]. Using this method,decision-makers involved in the procurement of MDEs
as well as clinical or financial administration staff score
technologies on a relevant and clearly defined set of cri-
teria – e.g. benefit to the patient population. The highest
scoring technologies are then procured. Such processes
may, however, be inherently biased: the experience of
decision-makers may not in fact reflect best available
evidence globally.
Table 2 Types of documents included in the systematic review and type of issuing organization
Research
institutions
or academic
groups
LMIC national
health authorities
International
consultants,
NGOs or
public health
monitoring
organizations
Hospitals
or health
care delivery
facilities
Medical
device
manufacturers
Government
sponsored donor
organizations
and the World
Bank
WHO
and UN
associate
Not
identified
Total
number of
documents
(% of total)
Article 47 8 25 16 2 25 2 125 (50%)
Guideline 1 2 6 25 34 (14%)
Manual 14 14 (6%)
Procurement
notice
10 1 11 (4%)
Recommendation 4 1 5 3 5 19 1 38 (15%)
Report 1 6 7 (3%)
Other 3 3 1 2 12 21 (8%)
Total number of
documents
(% of total)
52
(21%)
24
(10%)
40
(16%)
20
(8%)
2
(1%)
8
(3%)
101
(40%)
3
(1%)
250
Definitions: Research institutions or academic groups = Universities, specialist research bodies or collaborations; LMIC national health authorities = national
governments, government units or departments; International consultants, NGOs or public health monitoring organizations = Organizations such as Management
Sciences for Health, the Centre for Disease Control among others; Hospitals or health care delivery facilities = organizations with clinical health service delivery
remit; Medical device manufacturers = commercial entities and device suppliers; Government sponsored donor organizations and the World Bank = USAID, DFiD,
GIZ, CIDA and the WB; WHO and UN Associate = WHO, PAHO and UNDP, UNFPA, UNAIDS; Not identified = document authors solely, no identified
issuing organization
Article = peer-reviewed material published in academic journal or magazine; Bulletin = notification; Presentation = conference presentation or talk/speech;
Guideline = document identifying guiding principles and procedures; Procurement notice = tendering or bidding documents, initial advertisements of tender;
Recommendations = Research or review documents providing clearly stated summary recommendations; Report = document with pre-specified topic, may include
research evidence, discussion of current and best practice; Other = consultative document, evaluation/audit document, information booklets, policies, resolutions,
databases or spreadsheets, websites
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as particularly labour-, skill- and resource-intensive) [30]
could be used. For example, considering the use of cryo-
therapy for cervical intra-epithelial neoplasia, the WHO
commissioned independent systematic reviews of priority
topics relating to cervical neoplasia in women, selected a
panel of 14 multidisciplinary experts to review developed
GRADE evidence profiles and chaired a meeting during
which experts reached a consensus on key recommenda-
tions on the topic, including technology use.
Health technology assessment methods and routine
committee based evaluations of procurement processesTable 3 Particular countries and regions referenced in documents in
World Bank Country classification
Category Country/region (frequency of citation)
Low-income countries Benin (1), Guinea-Bissau (1), Congo (1), Mali (1)
(2), Kenya (1), Malawi (1), Morocco (1), Nepal (3
Lower-middle-income
countries
Bolivia (1), Cameroon (1), Guyana (1), Mongolia
Upper-middle-income
countries
South Africa (1), Peru (1), Brazil (3), China (2), Th
High-income countries Chile (1) b, USA (1) c
Regions Balkan countries (1), Eastern Europe (2), Africa
a Citations are made in 50 documents (one document may refer to more than one
b Chile was classified as an upper middle-income country up to 2014
c The USA is used as a comparator in one study[31] may be employed. PAHO recommends multi-
disciplinary committees involved in MDE procurement
draw on the evidence compiled by either national or re-
gional HTA bodies to reach purchasing decisions.
Procurement planning methods
Two main methods for MDE procurement planning in
LMICs were described in included documents. Firstly,
stakeholders may rely on experience to determine what
equipment to procure: e.g. past procurement and con-
sumption patterns are reviewed and used as a template for
reaching current and future decisions. For example, thiscluded a (frequencies of citation) grouped according to 2014
, Chad (1), Eritrea (1), Ethiopia (2), Gambia (1), Afghanistan (2), Bangladesh
), Tanzania (3), Uganda (1), Zimbabwe (1)
(1), Pakistan (1), Philippines (1), Vietnam, (1), Zambia (1), Lesotho (1)
ailand (1), Mexico (1)
(1)
country) Remaining documents reference LMICs generally
Table 4 Specific health conditions, disease areas and services/interventions cited across the included literature (frequencies of
citation) a
Health conditions and disease areas cited and frequency of citations Service areas/interventions cited and frequency of citations
AIDS/HIV and associated comorbidities 29 Interventions for reproductive, maternal and child health 23
Cancer 16 Surgery and trauma care 13
High burden diseases: diarrhoea, malaria, HIV, respiratory issues 7 Emergency medicine and disaster response 4
Malaria 5 Injection practices 2
Cardiological conditions 3 Imaging 2
Respiratory conditions, asthma and COPD 3 Blood safety; Forensic science; Primary care 1 each
Tropical diseases 2
Gastroenterological conditions 2
Tuberculosis 2
Bacteriological diseases and interventions; Measles; H1N1, H5N1;
Narcotic use; Renal disease; Non-communicable diseases; Fractures
and orthopaedic conditions; Cardiovascular disease
1 each
a Total n = 124, remaining documents do not include references to specific health conditions. (One document may reference more than one condition/clinical area)
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tional provided service delivery does not change [24].
Secondly, in contrast to experience-based methods,
needs-based procurement relies on stakeholders identi-
fying explicit health priorities at any given time and
agreeing service delivery targets based on context spe-
cific epidemiological information. For example, the
WHO Priority Medical Devices Availability MatrixFig. 3 Stakeholders and MDE procurement planning steps by health system
and qualitative summary of all available data; diagrams are descriptive accoun
at which they operate and the MDE procurement planning actions stakehold
summary goals that stakeholders at each level intend to meet in relation to Midentifies conditions corresponding to the highest global
(or national) burden of disease and indexes interventions
corresponding to these conditions [32]. Devices neces-
sary for carrying out each intervention are listed and
added to a ‘wish list’. Such methods thus identify presci-
ent health needs and evaluate procurement options in
the context of defined vertical/horizontal programs,
available budgets, present physical infrastructure andlevel*. *The above diagram was developed following narrative synthesis
ts of the literature. Stakeholders are grouped by the health system level
ers undertake are indicated. The coloured boxes on the right represent
DE procurement
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based methods may also rely on the development of
basic or advanced health care packages- e.g. see the
Basic Package for Primary Care Services by the Ministry
of Health in Afghanistan [19, 20].
In practice, stakeholders are reported to use mixed ap-
proaches. For example, CENETEC in Mexico uses histor-
ical procurement trends to recommend what equipment
to buy in clinical areas with little to no innovative or
updated practice, and needs-based methods to issue pro-
curement recommendations for national priority health
care areas such as tele-medicine or cancer care [36].
Factors considered in procurement planning
We distinguish factors considered in procurement plan-
ning from factors affecting the successful deployment
and use of MDEs in health facilities (See next section).
Figure 4 provides a visual representation of factors, in-
cluding evidence inputs, stakeholders consider when
reaching procurement decisions; we note the citation
frequency of each item and suggest this as a proxy for
the relative importance of the factor in decision-making.
Table 5 further summarizes frequent challenges and best
practices encountered for each of the above factors and
inputs.
Equipment cost, specialist recommendations and
technology regulatory approval are the primary factors
reported as influencing procurement decisions. Authors
of reviewed documents caution that procurementFig. 4 Citation frequency of factors and evidence inputs considered in prostakeholders underestimate the true cost of MDEs as
they neglect to consider maintenance, servicing and user
training requirements [1, 36–41]. Across the literature,
the input of specialists is recommended to ensure im-
proved technology procurement: e.g. biomedical engi-
neers can advise on maintenance/servicing/user training
issues, and health economists on the relative cost-
effectiveness of technologies [1, 39, 42–48]. Appraised
documents also cited international certification (e.g. ap-
proval by the FDA, a CE mark in the EU, inclusion in a
WHO prequalification scheme) as a proxy for technol-
ogy safety, a desired feature of MDEs to be procured
[38, 49, 50].
Evidence inputs identified across the literature include:
health needs assessment exercises/reports, clinical guide-
lines and health technology assessment exercises/re-
ports. The former factor is cited in relation to needs-
based procurement methods: i.e. routine health-needs
appraisals clarify national investment priorities [32]. Au-
thors of reviewed documents widely endorse the use of
clinical guidelines for technology selection; however note
these do not historically include clear technology invest-
ment/use recommendations [32]. We found MDE avail-
ability checklists and tools designed around clinical
guidelines [51–53].
Included documents additionally assign importance to
health technology assessment (HTA) exercises/reports
[39, 46]. Such evidence inputs are mentioned infre-
quently, and when present, studied authors comment oncurement planning
Table 5 Evidence inputs and factors considered in medical device procurement planning
Factors/ Evidence
input
Areas of concern in current
procurement planning processes
Selected key
references a
Recommended course of action to
address areas of concerns / best
practices:
Selected key
references a
Medical device cost: costs
considered for each product
purchase
Installation, maintenance and safe
disposal costs not captured;
User training costs not included;
SR143: WHO,
2011
SR122, 124–131:
WHO, 2010
Include all expenses associated
with medical device deployment
to health facilities, in particular
user training and maintenance;
SR241: Martin,
2005
SR247: Free, 1993
SR122, 124–131:
WHO, 2010
Specialist expertise: advice
or opinion of biomedical
engineers, health economists,
clinical or procurement specialists
considered when planning
Experts are rarely locally available;
Where experts are available,
expertise is likely financing/
pharmaceutical rather than
device specific;
SR79: Mullally,
2008
SR26: Mundy,
2012
SR34: Mundy,
2012
If possible, create national training
programs/specialized procurement
units staffed with biomedical
engineers;
Consult international biomedical
engineers or health economists
on specifications and value for
money of products;
SR63–69: Bloom,
1989
SR80: Mytton,
2010
Regulations and standards:
Equipment conformity to
international regulatory approval
(FDA approval, ISO certification,
CE mark)
Products complying with
international regulatory approvals
may be costly and unavailable in
local markets;
Absence of national regulatory
agencies impedes verification
of certifications;
SR163: WHO,
2012
SR133: WHO,
2011
As a minimum standard, ensure
high-risk equipment is internationally
certified for use so as to ensure
patient safety;
SR35: Keller, 2010
Health needs assessment:
Identified population health
priorities and/or technological
needs
National level decision-makers may
distrust needs-assessments conducted
by health facility personnel due to
exaggerations or mis-information;
Needs assessment information may
not be up to date;
SR38: Aid-
Khalet, 2001
SR56: Mavalankar,
2004
Create regional or national level
participatory structures where
health facility representatives may
directly participate in procurement
planning and tendering.
SR122, 124–131:
WHO, 2010
SR176: WHO, 2000
Clinical guidelines: Patient
management guidelines for
interventions/clinical areas
Clinical guidelines may not include
information on products needed to
carry out specific health interventions;
SR184: Anderson,
2008
Incorporate indications on medical
device necessities into clinical
guidelines and where possible
advise on LMIC friendly product
specifications.
SR41: Briggs, 2008
SR44: Dyer, 2010
Health technology assessment:
Methods and reports on the
procurement economic and health
impact, and policy and regulatory
approval
HTA difficult to undertake due to
data paucity on health impacts,
medical device coverage, equipment
life span, true costs of equipment.
SR24: PAHO,
2012
SR249:
Withanachchi,
2007
Within resource constraint, adopt
transparent and evidence-based
processes to evaluate different
investment options; If possible,
secure political support for HTA
implementation.
SR106: Panerai,
1989
SR198:
Teerawattananon,
2005
a Numbers with a prefix “SR” shown in the Table refer to identification numbers for documents included in the systematic review – please see Additional file 4 to
identify the individual references
Diaconu et al. Globalization and Health  (2017) 13:59 Page 9 of 16the difficulty of undertaking HTA (health economics in
particular) within resource constrained settings due to
data paucity, lack of specialist capacity and funding, and
a general lack of knowledge on how such evidence may
feed into decision making processes [1, 47, 48]. MICs,
however, have made substantial progress in the use of
HTA for the promotion of transparent and evidence-
based decision making: e.g. see HITAP in Thailand,
CENETEC in Mexico and a bill for the promotion of
HTA use across Latin America [31, 36, 47].
Factors affecting device deployment
We also extracted data on the factors cited as affecting
successful MDE uptake or use in LMICs. We provide a
visual representation of factors and citation frequency in
Fig. 5 and summarize frequent challenges and relevant
best practices in Table 6. Authors emphasise thatdecision-makers must carefully consider MDE technical
specifications and alignment to deployment setting infra-
structure, as well as ambient conditions and skills mix
encountered therein, before reaching a procurement
decision. We provide a summary of MDE design charac-
teristics most frequently mentioned by authors in Table
7 and suggest these as a starting point for specification
of desired technology characteristics or product triage
during procurement.
We note that factors cited as affecting MDE use in de-
ployment settings relate closely to the issues that authors
of reviewed documents suggest should be considered
during procurement planning: e.g. specialist expertise –
in the form of both biomedical engineering and clinical
knowledge – is needed to advise on what products are
suitable given a health facilities’ ambient conditions and
intended service delivery program. Similarly, a product’s
Fig. 5 Citation frequency of factors affecting successful device uptake in health facilities
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lation, maintenance, decommissioning and disposal ser-
vices that need to be put in place to support product
deployment; should human resource training be needed
this will additionally carry financial implications.
Prioritization of MDEs for procurement
One hundred and eleven of the 250 reviewed documents
indicate specific MDE prioritization methods and were in-
cluded in the meta-summary. Please see Additional file 6Table 6 Challenges affecting successful medical device uptake and
Challenge Consequences if ch
unaddressed
Device not aligned to healthcare delivery level and
general conditions encountered in deployment
setting (mix of skill mix, ambient conditions, referral
pathways)
Device cannot be u
premature disuse
Ambient conditions in deployment settings prevent the
use of the device;
Product cannot be
does not reach full
Health care personnel not trained in safe medical
device use or maintenance: devices not used safely and
do not reach full life-expectancy
Products used unsa
may experience ad
outcomes.
Device specifications to accord to the conditions
in which it is to be used: e.g. durability, humidity/
temperature resistance
No clear indication
device specification
Installation and preventive and corrective maintenance
services available (including necessary financing)
Lacking financial an
resources to carry o
/servicing of availab
Provision for safe medical device decommissioning and
disposal; including financial resources
Lacking financial an
resources to carry ofor a full account of findings generated and codes and
abstracted themes/topics developed during the meta-
summary; we restrict our discussion here to prioritization
criteria.
We identify six main prioritization criteria across
reviewed documents, which correspond to both norma-
tive and feasibility conditions, and list these in Fig. 6 ac-
cording to relative importance assigned in the literature.
Recurrent themes in the literature concern the identifi-
cation of priority health areas and services as well as theuse
allenge left Best practice
sed or falls into Consult clinical guidelines/experts
used; Product
life-expectancy;
Develop technological needs assessment: note present
conditions; consult LMIC friendly specification list
fely - patients
verse health
Provision of training manuals and supplier training for
any purchase
of LMIC friendly
s
Device specifications should conform to LMIC
environment and settings (see Table 7)
d human
ut maintenance
le devices
Installation and maintenance services should be
included as part of medical device procurement and
all ancillary costs considered in procurement
d human
ut
Identify decommissioning or disposal mechanisms and
consider any cost implications
Table 7 Medical device specifications and design desirable for
LMIC settings a
Design domain Specification
User friendliness Easy to use; rapid; low training needs
Portability Compact and portable (choose desktop variety if
theft is an issue)
Avoidance of bulky and heavy design
Reliance on external
factors
Elimination of external power sources
Include water purification system
Minimal need for sample preparation
Minimal need for spare parts
Design Long shelf-life at ambient temperature
Rapid
High sensitivity and specificity for diagnostic
technology
High throughput
Material Robust
Choice of durable material
a The above design characteristics were identified following thematic analysis
and coding of documents included in the qualitative meta-summary
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tings (See Table 7). For example, the WHO, USAID and
UNFPA all recommend prioritizing MDEs used in inter-
ventions addressing prominent disease burdens and that
support existing health service delivery efforts [27, 32,
54]. Purchases are further screened and prioritized ac-
cording to their suitability to LMIC settings: i.e. MDEs
for which no trained professionals are present or whichFig. 6 Prioritization criteria extracted from reviewed literature (% indicate m
meta-summary presented in Additional file 6. Criteria relate to the thematic
prioritization processes. Effect sizes are calculated as per Sandelowski et al.lack established maintenance or decommissioning ser-
vices are deprioritized for purchase [28, 36, 38, 55–57].
Budget constraints, experiences gained in past pro-
curement cycles, political/cultural support and equity
considerations also influence prioritization decisions.
Current and future budget impact is balanced against
evaluations of past procurement performance: e.g. if sup-
ply chains are not present to source a particular technol-
ogy, this is either deprioritized or alternative sources for
investment identified [58]. Non-invasive, culturally ac-
ceptable technologies with records of accomplishment
and safe use are preferred; however, in practice, tech-
nologies endorsed by political groups may further bypass
normal prioritization or decision-making channels and
be procured due to strong advocacy [59].
Patterns in extracted texts suggest different types of
criteria are considered at different decision making-
levels (Fig. 7). We interpret this as stakeholders at each
health-system level undertaking/being responsible for
different prioritization steps. For example, micro-level
stakeholders - i.e. health care professionals in individual
health facilities - prioritize equipment according to tech-
nical specifications and design: portable, durable,
electric-surge resistant equipment is preferred [60, 61].
Meso-level stakeholder - i.e. regional and specialist
?authorities engaged in procurement planning in the
context of interventions/programs-in turn prioritizeeta-summary effect size)*. *The above criteria were distilled from the
analysis conducted across the 111 documents noting explicit MDE
and indicate the % of documents citing a specific theme
Fig. 7 Medical device prioritization: decision-making issues and criteria considered at different health system levels*. *Following on from the
qualitative meta-summary, we grouped the decision-making issues and criteria identified via thematic analysis by health system level. Issues and
criteria are descriptive findings synthesized across documents
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<?A3B2 thyc=long-term use, and ideally cost-effective
[35, 62]. This meta-summary is descriptive in relation-
ship to health system levels and roles but presents nor-
mative criteria although the descriptive and normative
were not always clearly delineated in the source
documents.
Distilled recommendations
Table 8 provides a descriptive synthesis of normative
MDE procurement and prioritization accounts reviewed.
All findings reported are descriptive in that we
synthesize theories and positions articulated within the
reviewed literature: as part of this literature includes
normative accounts, we have additionally synthesized
these for those documents reporting specifically on
prioritization of MDEs for procurement. We synthesise
key recommendations and best practices and offer these
for the consideration of procurement officials and MDE
researchers.
Discussion and conclusions
The current paper is the first review to systematically
appraise and summarize the LMIC medical device
procurement literature. We acknowledge some limita-
tions. First, the LMIC MDE specific procurement litera-
ture is highly heterogeneous; our search and selectionalgorithms were therefore deliberately broad. The review
thus provides not only a synthesis of the available litera-
ture but also serves as a hypothesis generating exercise
meant to direct future research efforts and inform
current procurement professionals of key recommenda-
tions in the global literature. Second, when appraising
and synthesising information across texts, it was not al-
ways possible to distinguish descriptive and normative
MDE procurement accounts: i.e. what happens in prac-
tice vs. what ought to happen. Despite this, we offer
readers a structured account of the reported methods,
factors and prioritization criteria considered for MDE
procurement.
The heterogeneity of documents reviewed, specifically
the diverse bibliographic literature (e.g. ranging from
cost-effectiveness evaluations to guidance on the use of
health technology assessments methods for procure-
ment) and large proportion of grey literature included in
this review, made assessments of the risk of bias imprac-
tical. We acknowledge this as a limitation and caution
readers to reflect on findings carefully.
We acknowledge substantial difficulties in sourcing
documents for full-text review. While we appraised sev-
eral digitized abstracts, it was not always possible to lo-
cate ancillary digital full-text versions of documents of
interest: while we are confident that these documents
cannot be openly accessed, we were unable to assess any
Table 8 A synthesis of recommendations expressed in the literature for consideration by international donors, LMIC stakeholders
and the international research community a
Recommendation Explanation
Close the feedback loop The WHO deplores the mismatch created by low-resource settings procuring high-end technologies. (1)
Authors in the literature recommend LMICs and donor institutions evaluate past procurement efforts and
create participatory structures for health facility representatives to engage in planning/procurement
consultations. This increases transparency and pre-empts technology adoption/use issues by informing
all stakeholders of health facility needs/infrastructure/skill mix.
Fully cost out potential purchases Authors in the literature note discrepancies in costing practices, we therefore recommend national
costing templates are created and disseminated to facilities and procurement agents for MDE purchases.
Costing templates should be context specific and include:
a) Expenses related to equipment installation, servicing (inspection, installation, preventive and corrective
maintenance, decommissioning and disposal);
b) Investments into infrastructural refurbishments of deployment health facilities and user training that
would aid in keeping MDEs operational.
The WHO Cost-It templates present a good starting point for this at hospital or program level. We remind
users to include inspection, installation and decommissioning/disposal costs in templates under the ‘other’
headings. (75)
Make MDE servicing a legal requirement Authors in the literature recommend LMIC regulatory agents develop minimum, legally binding, standards
for national/regional MDE servicing.
Procured equipment should be subject to specialist inspection and installation once in deployment
settings; service provisions/funding allowances for preventive and corrective maintenance,
decommissioning and disposal should be identified before tendering.
Include explicit MDE availability
recommendations in clinical guidelines.
We note that historically clinical guidelines do not include specific recommendations on what medical
devices should be available for specific interventions - authors note this as an issue for biomedical
engineers or procurement agents engaged in product selection.
Develop a list of generic specifications for
LMIC friendly equipment.
Authors in the literature recommend the elaboration and listing of generic medical device and equipment
technical
specifications to aid LMIC procurers. The list of broad product features we have identified in this review is
a start in this endeavor, but international engineering expertise is needed to create technical specifications
or target product profiles specific to LMICs (Table 7).
Abbreviations: MDE Medical devices and equipment, LMICs Low- and Middle-income Countries
a This synthesis was developed following on from the narrative synthesis and meta-summary. It reflects the authors’ reflections on themes and issues emphasized
in the literature
Diaconu et al. Globalization and Health  (2017) 13:59 Page 13 of 16bias associated with availability. We additionally note
that our findings reflect the state of the literature up to
2013. Further documents of relevance to MDE procure-
ment have been published in recent years (e.g. [63, 64]),
however to our knowledge, such documents represent
updates or continuation of literature included here ra-
ther than research into the specific MDE procurement
methods relevant for LMICs.
The comprehensive synthesis of information, as well
as the granular pragmatic recommendations distilled
across documents, are the principal strengths of this sys-
tematic review. In our narrative synthesis we identify
two general methods for MDE procurement planning,
which stakeholders appear to combine in practice:
experience-based methods rely on the perceived success
of previous purchase rounds; need-based methods in-
stead identify current health needs and develop bespoke
technology procurement plans to tackle these. Overall,
we find no established consensus on how LMIC based
MDE procurement should occur, but we note the litera-
ture converging on what evidence inputs and factors
should be considered in decision-making.
The findings of the meta-summary echo previous work
on the normative and feasibility criteria considered bydecision makers in technology investment and
prioritization [65–68]. In contrast to previous conclu-
sions emphasizing the relevance of normative criteria,
however, we note that MDE procurement is chiefly
driven by feasibility concerns: i.e. as MDEs run the sub-
stantial risk of being unused due to technology misalign-
ment to deployment settings, decision makers most
value products with appropriate technical specifications
and established maintenance services. We recommend
further research be undertaken to support the develop-
ment and validation of a unified set of criteria able to
guide LMIC medical device and equipment procure-
ment. Criteria identified within this paper may serve as a
first draft of such a document. Further research may
additionally explore differences between international
and national guidelines on the topic, as well as national
guidelines and sub-national practices.
Our findings further suggest that MDE procurement
within LMICs presents substantial differences to tech-
nology procurement within HICs. While individual
health facilities may have the capacity to directly tender
in the latter settings, we have noted this practice is not
consistent across LMICs. HICs further use health tech-
nology assessment agencies and health economic
Diaconu et al. Globalization and Health  (2017) 13:59 Page 14 of 16principles and methods to select technologies appropri-
ate for reimbursement and advise on the containment of
health care costs [69, 70]. In this review, only a fifth of
documents reference such methods for MDE procure-
ment. Difficulties in using such methods for LMICs are
widely noted in the literature and have more recently been
summarized in the 2015 Global Survey on Health Tech-
nology Assessment; political, cultural and specialist sup-
port for the use of such methods is lacking and the
necessary data on local epidemiology, costs and treatment
impact for LMICs is also scarce [71]. We contend, how-
ever, that such efforts are recommended for the develop-
ment of transparent and rational procurement practices
[68, 72, 73]. We developed a decision algorithm incorpor-
ating health economic methods that may be suitable for
LICs with little specialist capacity elsewhere [74] and dir-
ect readers to further valuable resources on this topic [68,
73, 75].
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